{
    "relation": [
        [
            "Arms",
            "Active Comparator: AMG 151 - Arm 1 AMG 151 - Arm 1",
            "Active Comparator: AMG 151 - Arm 2 AMG 151 - Arm 2",
            "Active Comparator: AMG 151 - Arm 3 AMG 151 - Arm 3",
            "Active Comparator: AMG 151 - Arm 4 AMG 151 - Arm 4",
            "Active Comparator: AMG 151 - Arm 5 AMG 151 - Arm 5",
            "Active Comparator: AMG 151 - Arm 6 AMG 151 - Arm 6",
            "Placebo Comparator: Placebo Arm AMG 151 Placebo Arm"
        ],
        [
            "Assigned Interventions",
            "Drug: AMG 151 Drug: AMG 151 50 mg BID Drug: Metformin Subjects will remain on their metformin regimen throughout the study. The metformin dose must be \u2265 850 mg/day for at least 2 months immediately prior to randomization.",
            "Drug: Metformin Subjects will remain on their metformin regimen throughout the study. The metformin dose must be \u2265 850 mg/day for at least 2 months immediately prior to randomization. Drug: AMG 151 Drug: AMG 151 100 mg BID",
            "Drug: Metformin Subjects will remain on their metformin regimen throughout the study. The metformin dose must be \u2265 850 mg/day for at least 2 months immediately prior to randomization. Drug: AMG 151 Drug: AMG 151 200 mg BID",
            "Drug: Metformin Subjects will remain on their metformin regimen throughout the study. The metformin dose must be \u2265 850 mg/day for at least 2 months immediately prior to randomization. Drug: AMG 151 Drug: AMG 151 100 mg QD",
            "Drug: Metformin Subjects will remain on their metformin regimen throughout the study. The metformin dose must be \u2265 850 mg/day for at least 2 months immediately prior to randomization. Drug: AMG 151 Drug: AMG 151 200 mg QD",
            "Drug: Metformin Subjects will remain on their metformin regimen throughout the study. The metformin dose must be \u2265 850 mg/day for at least 2 months immediately prior to randomization. Drug: AMG 151 Drug: AMG 151 400 mg QD",
            "Drug: Placebo Placebo Drug: Metformin Subjects will remain on their metformin regimen throughout the study. The metformin dose must be \u2265 850 mg/day for at least 2 months immediately prior to randomization."
        ]
    ],
    "pageTitle": "AMG 151 Amgen Protocol Number 20100761 - Full Text View - ClinicalTrials.gov",
    "title": "",
    "url": "https://clinicaltrials.gov/ct2/show/study/NCT01464437",
    "hasHeader": true,
    "headerPosition": "FIRST_ROW",
    "tableType": "RELATION",
    "tableNum": 3,
    "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438042991951.97/warc/CC-MAIN-20150728002311-00290-ip-10-236-191-2.ec2.internal.warc.gz",
    "recordEndOffset": 853732247,
    "recordOffset": 853719246,
    "tableOrientation": "HORIZONTAL",
    "textBeforeTable": "October 2012 (Final data collection date for primary outcome measure) Primary Completion Date: December 2012 Study Completion Date: September 2011 Study Start Date: 236 Enrollment: Adverse events [\u00a0Time\u00a0Frame:\u00a0Incidence of serious adverse events from signing of ICF to Day 42. Incidence of non-serious adverse events from randomization to Day 42.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0] To assess the effect of AMG 151 on postprandial glucose levels in response to a meal tolerance test [\u00a0Time\u00a0Frame:\u00a0Change in area under the curve from 0-4 hours (AUC0-4hr) glucose after a meal tolerancetest from baseline to Day 28, Change in incremental AUC0-4hr glucose after a meal tolerance test from baseline to Day 28\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0] Secondary Outcome Measures: To evaluate the dose-effect relationship of AMG 151 compared to placebo on fasting plasma glucose in subjects with type 2 diabetes treated with metformin [\u00a0Time\u00a0Frame:\u00a0Change in fasting plasma glucose levels from baseline to Day 28\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0] Primary Outcome Measures:",
    "textAfterTable": "\u00a0 Eligibility Ages Eligible for Study: \u00a0 18 Years to 75 Years Genders Eligible for Study: \u00a0 Both Accepts Healthy Volunteers: \u00a0 No Criteria Inclusion Criteria: Age 18 to 75 years, inclusive Diagnosis of type 2 diabetes mellitus HbA1c levels 7.5% to 11.0%, inclusive, at screening Fasting C-peptide levels \u2265 0.2 nmol/L at screening BMI \u2265 25 to < 45 kg/m2 at screening Treated with metformin monotherapy for at least 3 months prior to randomization; the metformin dose must be \u2265 850 mg daily for at least 2 months immediately prior to randomization If a subject is being treated for hyperlipidemia or hypertension they should be on stable medication for 30 days before randomization Subject has provided informed consent. Exclusion Criteria: History of type 1 diabetes History of significant weight gain or loss (> 10%) during the 4 weeks before randomization Use of any weight loss medication (over",
    "hasKeyColumn": false,
    "keyColumnIndex": -1,
    "headerRowIndex": 0
}